RUNX1 and fungal infectious disease: Of note, 70% of AML patients developed an IFD, while only 2.4% of ALL cases (1/42; with ETV6::RUNX1 fusion and under the high-risk protocol due to high measurable residual disease during induction) manifested an invasive fungal infection.